Overview

A Study of OKI-179 in Patients With Solid Tumors

Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
This study is a Phase 1, single center, open-label study, assessing single agent dose escalation of OKI-179.
Phase:
Phase 1
Details
Lead Sponsor:
OnKure, Inc.
Collaborator:
University of Colorado, Denver